Sanofi (SNY) Lowered to “Hold” at Zacks Investment Research

Sanofi (SNY) Lowered to “Hold” at Zacks Investment Research

Zacks Investment Research lowered shares of Sanofi (NYSE:SNY) from a buy rating to a hold rating in a report issued on Tuesday.

According to Zacks, “Sanofi’s focus on streamlining its business and pursuing business development deals is encouraging. Meanwhile, Sanofi has several new products in its portfolio and candidates in its pipeline that can contribute to long-term growth. Products like Toujeo, Aubagio and Lemtrada are likely to do well. Sanofi’s shares outperformed the large-cap pharma group this year. Estimates have increased slightly ahead of the company’s Q4 earnings release. The company has a positive record of earnings surprises in recent quarters. However, Sanofi’s Diabetes franchise is under significant pressure with key product, Lantus, facing intense competitive pressure at the payor level and the presence of biosimilar competition in several European markets and Japan. Sanofi’s outlook for its Diabetes franchise is also bleak. Other headwinds include generic competition and slower-than-expected uptake of new products like Praluent.”

A number of other research analysts also recently commented on SNY. Goldman Sachs Group, Inc. (The) initiated coverage on Sanofi in a report on Monday, November 7th. They issued a neutral rating on the stock. Morgan Stanley upgraded Sanofi from an equal weight rating to an overweight rating in a report on Tuesday, November 29th. Finally, Leerink Swann reiterated an outperform rating on shares of Sanofi in a report on Tuesday, January 10th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the company. Sanofi presently has a consensus rating of Hold and an average price target of $60.50.

Shares of Sanofi (NYSE:SNY) traded up 2.41% on Tuesday, reaching $41.22. The company’s stock had a trading volume of 1,931,667 shares. The company has a market capitalization of $106.10 billion, a price-to-earnings ratio of 23.51 and a beta of 0.98. The stock has a 50-day moving average price of $40.31 and a 200-day moving average price of $39.70. Sanofi has a 1-year low of $36.81 and a 1-year high of $44.50.

Hedge funds have recently bought and sold shares of the company. Boston Partners boosted its stake in Sanofi by 19.8% in the third quarter. Boston Partners now owns 8,868,295 shares of the company’s stock valued at $338,680,000 after buying an additional 1,466,286 shares in the last quarter. Hotchkis & Wiley Capital Management LLC boosted its stake in Sanofi by 12.5% in the second quarter. Hotchkis & Wiley Capital Management LLC now owns 11,432,112 shares of the company’s stock valued at $478,434,000 after buying an additional 1,267,118 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Sanofi by 30.9% in the third quarter. Wells Fargo & Company MN now owns 3,973,784 shares of the company’s stock valued at $151,760,000 after buying an additional 938,683 shares in the last quarter. Paulson & CO. Inc. acquired a new stake in Sanofi during the second quarter valued at approximately $16,552,000. Finally, Aviance Capital Management LLC boosted its stake in Sanofi by 72.4% in the third quarter. Aviance Capital Management LLC now owns 798,327 shares of the company’s stock valued at $30,488,000 after buying an additional 335,386 shares in the last quarter. 9.73% of the stock is owned by institutional investors.

Sanofi Company Profile

Sanofi SA, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. It operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.

Get a free copy of the Zacks research report on Sanofi (SNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment